141 related articles for article (PubMed ID: 23986614)
1. Role of quantitative pharmacokinetic parameter (transfer constant: K(trans)) in the characterization of breast lesions on MRI.
Amarnath J; Sangeeta T; Mehta SB
Indian J Radiol Imaging; 2013 Jan; 23(1):19-25. PubMed ID: 23986614
[TBL] [Abstract][Full Text] [Related]
2. [Diagnostic value of quantitative pharmacokinetic parameters and relative quantitative pharmacokinetic parameters in breast lesions with dynamic contrast-enhanced MRI].
Sun TT; Liu WH; Zhang YQ; Li LH; Wang R; Ye YY
Zhonghua Yi Xue Za Zhi; 2017 Aug; 97(29):2266-2270. PubMed ID: 28780840
[No Abstract] [Full Text] [Related]
3. 3-T dynamic contrast-enhanced MRI of the breast: pharmacokinetic parameters versus conventional kinetic curve analysis.
El Khouli RH; Macura KJ; Kamel IR; Jacobs MA; Bluemke DA
AJR Am J Roentgenol; 2011 Dec; 197(6):1498-505. PubMed ID: 22109308
[TBL] [Abstract][Full Text] [Related]
4. Differentiation of Benign from Malignant Adnexal Masses by Dynamic Contrast-Enhanced MRI (DCE-MRI): Quantitative and Semi-quantitative analysis at 3-Tesla MRI.
Gity M; Parviz S; Saligheh Rad H; Fathi Kazerooni A; Shirali E; Shakiba M; Baikpour M
Asian Pac J Cancer Prev; 2019 Apr; 20(4):1073-1079. PubMed ID: 31030476
[TBL] [Abstract][Full Text] [Related]
5. Optimizing MRI scan time in the computation of pharmacokinetic parameters (K(trans) ) in breast cancer diagnosis.
Jena A; Mehta SB; Taneja S
J Magn Reson Imaging; 2013 Sep; 38(3):573-9. PubMed ID: 23349046
[TBL] [Abstract][Full Text] [Related]
6. Role of pharmacokinetic parameters derived with high temporal resolution DCE MRI using simultaneous PET/MRI system in breast cancer: A feasibility study.
Jena A; Taneja S; Singh A; Negi P; Mehta SB; Sarin R
Eur J Radiol; 2017 Jan; 86():261-266. PubMed ID: 28027758
[TBL] [Abstract][Full Text] [Related]
7. Application of whole-lesion histogram analysis of pharmacokinetic parameters in dynamic contrast-enhanced MRI of breast lesions with the CAIPIRINHA-Dixon-TWIST-VIBE technique.
Li Z; Ai T; Hu Y; Yan X; Nickel MD; Xu X; Xia L
J Magn Reson Imaging; 2018 Jan; 47(1):91-96. PubMed ID: 28577335
[TBL] [Abstract][Full Text] [Related]
8. Multiparametric approach with diffusion-weighted imaging and dynamic contrast-enhanced MRI: a comparison study for differentiating between benign and malignant bone lesions in adults.
Oh E; Yoon YC; Kim JH; Kim K
Clin Radiol; 2017 Jul; 72(7):552-559. PubMed ID: 28325514
[TBL] [Abstract][Full Text] [Related]
9. Radiomics Based on Multimodal MRI for the Differential Diagnosis of Benign and Malignant Breast Lesions.
Zhang Q; Peng Y; Liu W; Bai J; Zheng J; Yang X; Zhou L
J Magn Reson Imaging; 2020 Aug; 52(2):596-607. PubMed ID: 32061014
[TBL] [Abstract][Full Text] [Related]
10. Discrimination between benign and malignant breast lesions using volumetric quantitative dynamic contrast-enhanced MR imaging.
Cheng Z; Wu Z; Shi G; Yi Z; Xie M; Zeng W; Song C; Zheng C; Shen J
Eur Radiol; 2018 Mar; 28(3):982-991. PubMed ID: 28929243
[TBL] [Abstract][Full Text] [Related]
11. Separation of benign and malignant breast lesions using dynamic contrast enhanced MRI in a biopsy cohort.
Kim SG; Freed M; Leite APK; Zhang J; Seuss C; Moy L
J Magn Reson Imaging; 2017 May; 45(5):1385-1393. PubMed ID: 27766710
[TBL] [Abstract][Full Text] [Related]
12. Intravoxel incoherent motion MR imaging for breast lesions: comparison and correlation with pharmacokinetic evaluation from dynamic contrast-enhanced MR imaging.
Liu C; Wang K; Chan Q; Liu Z; Zhang J; He H; Zhang S; Liang C
Eur Radiol; 2016 Nov; 26(11):3888-3898. PubMed ID: 26863896
[TBL] [Abstract][Full Text] [Related]
13. Use of diffusion kurtosis imaging and quantitative dynamic contrast-enhanced MRI for the differentiation of breast tumors.
Li T; Yu T; Li L; Lu L; Zhuo Y; Lian J; Xiong Y; Kong D; Li K
J Magn Reson Imaging; 2018 Nov; 48(5):1358-1366. PubMed ID: 29717790
[TBL] [Abstract][Full Text] [Related]
14. Discrimination of benign and malignant breast lesions by using shutter-speed dynamic contrast-enhanced MR imaging.
Huang W; Tudorica LA; Li X; Thakur SB; Chen Y; Morris EA; Tagge IJ; Korenblit ME; Rooney WD; Koutcher JA; Springer CS
Radiology; 2011 Nov; 261(2):394-403. PubMed ID: 21828189
[TBL] [Abstract][Full Text] [Related]
15. Quality-based pharmacokinetic model selection on DCE-MRI for characterizing orbital lesions.
Lecler A; Balvay D; Cuenod CA; Marais L; Zmuda M; Sadik JC; Galatoire O; Farah E; El Methni J; Zuber K; Bergès O; Savatovsky J; Fournier L
J Magn Reson Imaging; 2019 Nov; 50(5):1514-1525. PubMed ID: 30989761
[TBL] [Abstract][Full Text] [Related]
16. Accuracy and precision of quantitative DCE-MRI parameters: How should one estimate contrast concentration?
Wake N; Chandarana H; Rusinek H; Fujimoto K; Moy L; Sodickson DK; Kim SG
Magn Reson Imaging; 2018 Oct; 52():16-23. PubMed ID: 29777820
[TBL] [Abstract][Full Text] [Related]
17. Optimized Fast Dynamic Contrast-Enhanced Magnetic Resonance Imaging of the Prostate: Effect of Sampling Duration on Pharmacokinetic Parameters.
Othman AE; Falkner F; Martirosian P; Schraml C; Schwentner C; Nickel D; Nikolaou K; Notohamiprodjo M
Invest Radiol; 2016 Feb; 51(2):106-12. PubMed ID: 26447494
[TBL] [Abstract][Full Text] [Related]
18. Blood Oxygenation Level Dependent Magnetic Resonance Imaging (MRI), Dynamic Contrast Enhanced MRI, and Diffusion Weighted MRI for Benign and Malignant Breast Cancer Discrimination: A Preliminary Experience.
Fusco R; Granata V; Mattace Raso M; Vallone P; De Rosa AP; Siani C; Di Bonito M; Petrillo A; Sansone M
Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34067721
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic approach for dynamic breast MRI to indicate signal intensity time curves of benign and malignant lesions by using the tumor flow residence time.
Renz DM; Diekmann F; Schmitzberger FF; Pietsch H; Fallenberg EM; Durmus T; Huppertz A; Böttcher J; Bick U; Hamm B; Lawaczeck R
Invest Radiol; 2013 Feb; 48(2):69-78. PubMed ID: 23262793
[TBL] [Abstract][Full Text] [Related]
20. Distinguishing benign and malignant breast tumors: preliminary comparison of kinetic modeling approaches using multi-institutional dynamic contrast-enhanced MRI data from the International Breast MR Consortium 6883 trial.
Sorace AG; Partridge SC; Li X; Virostko J; Barnes SL; Hippe DS; Huang W; Yankeelov TE
J Med Imaging (Bellingham); 2018 Jan; 5(1):011019. PubMed ID: 29392160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
